{"id":"W2753432434","doi":"10.1056/nejmoa1709684","title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5392,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ipilimumab; Nivolumab; Medicine; Melanoma; Oncology; Internal medicine; Overall survival; Metastatic melanoma; Clinical trial; Immunotherapy; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}